key: cord-0719751-pepeja37 authors: Mei, P. A.; Loeb, L. title: COVID-19: A Chronological Review of the Neurological Repercussions - What do We Know by May, 2020? date: 2020-05-26 journal: nan DOI: 10.1101/2020.05.19.20107102 sha: 0c4cac3d1ec50cc99d7c7daad18299a997899094 doc_id: 719751 cord_uid: pepeja37 Abstract Introduction: Despite the new SARS-CoV-2 (COVID-19) be the seventh of the coronavirus family viruses known to cause human disease, little is known about potential symptoms and syndromes secondary to the compromise of the central and peripheral nervous systems. We reviewed neurological manifestations due to the new coronavirus, thus far published in the literature, as well as guidelines issued by sub-specialties in Neurology, to tackle the disease. Methods: we searched medical databases, such as PubMed, PubMed Central, LILACS and Google scholar for papers (case reports, short letters, case series, etc) describing neurological symptoms in patients with confirmed or suspect COVID-19 diagnosis and also searched webpages of associations and organizations that deal with neurological disorders. Results: we describe briefly each article considered for this review. Forty-one papers were found associating neurological conditions and COVID-19. Cases are divided by disease groups and, within each disease group, results are listed in chronological order or publication date. We also discuss briefly recommendations for neurological patients, according to disease group. Conclusion: Although there is evidence of neurological manifestations with previous coronaviruses, COVID-19 is assuring a volume of published papers not seen before for other coronavirus infections. Most neurological cases are not life-threatening, but 10 to 20% of cases will require hospitalization and are in risk for sequelae and death. Although a lot of data coming from these papers is amassing, researchers must bear in mind that many papers currently published are not yet peer-reviewed, and thus are prone to further corrections. There is increasing evidence that SARS-CoV-2 is a systemic infection that reaches different organs and systems, including the nervous system by either direct and/or indirect routes (4). This is largely expected, based on knowledge of previous coronavirus infections, particularly from the more recent waves of SARS (5) (6) (7) and MERS -Middle East Respiratory Syndrome (8) (9) (10) (11). Both diseases account for at least 15 case reports in the literature of neurologic complications related to infections (12) . Table 1 encompasses some examples of case reports published regarding those two viruses and their neurological complications. Among more ancient strains, OC43 is notably associated with cases of neuronal and glial inflammation, the most severe a fatal case of encephalitis in an 11-month-old boy with congenital immunodeficiency, described in 2016 (13) . Post-mortem immunohistochemical analysis allowed the identification of viral particles within the neuropil. Central Nervous System (CNS), Peripheral Nervous System (PNS) and neurovascular conditions, like viral meningitis, anosmia/hyposmia, encephalitis end encephalopathy, Guillain-Barré Syndrome (GBS), myositis, cranial nerve palsy, stroke, and others have been linked to SARS-CoV-2, making it extremely important for health professionals to better understand the link between this pathogen and its neurological repercussions. We present a review of current data available on the neurological consequences of the new coronavirus. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint We did a systematic review of papers published in English, up to May 14 th , 2020. PubMed and PubMed Central (14), EMBASE (15), LILACS (16) , and Google Scholar (17) databases were searched. Articles meeting the association between the terms "neurology", "nervous system", "neurological", "Guillain Barré", "muscle", "rhabdomyolysis", "CSF", "cerebrospinal", "intensitve care", "ICU", "critical", "EEG", "epilepsy", "seizures", or "spinal fluid" AND either "COVID-19", "SARS-CoV-2", "coronavirus", "2019-nCoV", "MERS" and "SARS" were accessed. Later, we searched all those databases and included a broader search in Google (18), for "neurology", "nervous system", "neurological", AND "guidelines", "society", or "recommendations". For neurological cases, only papers published in scientific journals, with or without peer review, were included. For guidelines, websites of recognized scientific organizations and associations were also accepted. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint We found 41 articles consisting of case reports or series of cases with nervous system compromise by the new SARS-CoV-2, plus a variety of statements and documents issued by associations, with guidelines to neurologists and patients. Articles come from a variety of countries, mainly USA, China, Iran and Italy. Figure 1 shows all countries where articles encountered come from. We must emphasize that, at this point, and due to the rush to gather information that current times require, the majority of articles found and cited are yet to be peerreviewed and, therefore, modified and corrected. We will discuss the findings below, which are separated by topics regarding disease groups affecting the CNS, PNS, and neurovascular system, as well as guidelines issued by specific organizations, to tackle COVID-19 complications. In each segment, articles are enlisted in the chronological order they've been published. Table 2 displays a summary of those articles. Readers should likewise keep in mind that we do not analyze in deep the general clinical situation of cases, as the main focus remains on neurological symptoms. However, when required, information about other systems is covered in the description. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint In an analysis of 214 patients infected with COVID-19 in Wuhan, China (19) , published in February 25, 2020, 78 (36.4%) manifested neurological symptoms, being dizziness (16.8%), headache (13.1%), muscular pain/injury (10.7%), impaired consciousness (7.5%), hypogeusia (5.6%) and hyposmia (5.1%) the most commonly reported. In another series of 58 patients admitted in two Intensive Care Units (ICUs) with confirmed SARS-CoV-2 in Strasbourg, France, published on April 15, 2020, Helms et al. (20) verified neurologic symptoms in 49 (85%). A few patients presented these symptoms at admission, and the majority after withholding of sedation and neuromuscular blockers. Of seven patients that underwent spinal tap, only one had an elevation of Immunoglobulin G and proteins. All cases had negative results for PCR research for SARS-CoV-2 in the CSF. We will disclose disease groups of cases so far published in the topics ahead. Table 3 lists cases described separated by disease groups, as well as the number of patients bearing each condition. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint 1 -w e o p t e d t o i n c l u d e E n c e p h a l i t i s a n d E n c e p h a l o p a t h y o n t h e s a m e g r o u p , a s t h e d i s t i n c t i o n a m o n g b o t h e n t i t i e s i s n o t a l w a y s c l e a r . A l s o , c a s e s w i t h n e w l y -o n s e t e p i l e p s y w e r e c o n s i d e r e d h e r e , a s w e a s s u m e t h a t , i n p a t i e n t s w i t h n o p a s t n e u r o l o g i c a l i s s u e s , s e i z u r e s a r e a d i r e c t r e s u l t o f v i r a l i n f e c t i in FLAIR and T2 in the same area and also in the bilateral, mesial temporal regions, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint Researchers from Lausanne, Switzerland, report on May 07, 2020 (34) , two female patients, aged 64 and 67, the first with psychosis and seizures, and the second with headache and stupor. Brain MRI was normal for both, and CSH presented lymphocytosis and was negative for PCR for SARS-CoV-2. Zhao and other doctors of the Hubei province, China (35) depict on April 09, 2020, a case of a 66-year-old man with respiratory symptoms and SARS-CoV confirmed by nasopharyngeal swab PCR who later developed flaccid paraparesis with compromise of the sphincters (urinary and bowel incontinence). Neurological examination revealed sensory loss below the T10 level. Brain CT revealed chronic abnormalities (atrophy, lacunar infarction). CSF and MRI were not obtained. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. In a correspondence letter by Galougahi and colleagues (38), on April 11, 2020, a 27year-old male patient from Tehran, Iran, was submitted to MRI of the olfactory bulbs, after having confirmation for COVID-19 by PCR. Anosmia was the only complaint, but it is not stated how many days before imaging the symptoms had started. They state that different from this patient, it is not unusual to find reduction of olfactory bulbs volume after a viral infection, correlating to the loss of smell, and conclude that more patients . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Italian experts report on April 29, 2020 (44) , the story of a male, aged 71, hypertense, previously treated for lung cancer, referred to the emergency department due to subacute paresthesia in the lower limbs that evolved in three days to severe, flaccid tetraparesis, without cranial nerve impairment. CT of the head was unexceptional. Spinal tap displayed mild elevation of cells -9 leukocytes/µL, and protein -54 mg/mL. PCR of the nasopharynx was positive, and of the CSF was negative for COVID-19. Nerve conduction showed a neuropathy of predominantly demyelinating features. On May 12, 2020, Ottaviani and colleagues (45) describe a 66-year-old woman with impairment of gait and fatigue 3 days prior to admission, and a longer history (10 days) of respiratory symptoms. Nerve conduction studies (NCS) showed prolonged waves, denoting a demyelinating GBS syndrome. CSF showed no cells and protein level of 108 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. MRI displayed T2 hyperintensity and enlargement of the left oculomotor nerve. As he also had paresthesia and ataxia, he was diagnosed with Miller Fisher Syndrome, a variant of GBS, and was treated with immunoglobulin and hydroxychloroquine, being discharged with improvement three days later. Ganglioside panel was negative for antibodies. They also report a woman, aged 71, with painless diplopia, having had a cough and fever in the past days. MRI revealed the enhancement of both optic nerve sheaths. CSF had normal opening pressure, cellularity, and biochemistry. She was treated with hydroxychloroquine for pneumonia and later discharged with the perseverance of abduction palsy of the right eye, showing slow recovery in the following days. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint Jin and Tong, from Wuhan, China, report on March 20, 2020 (48), a man, aged 60, with respiratory distress and fever. The oropharyngeal swab was positive for SARS-CoV-2. Creatine kinase (CK) was normal at admission, so was kidney function, and lactate dehydrogenase (DHL) was slightly elevated -280 U/L (upper limit 245). Nine days later, he displayed pain in the lower limbs, CK was 11,842 U/L, DHL was 2,347 U/L. He was treated with fluid therapy, lopinavir, and moxifloxacin, improving symptoms some days later. (49) report, on April 06, 2020, in New York, USA, a male patient, aged 88, with lower limbs weakness and pain. He was hypertense, dyslipidemic -used statins for several years, had benign prostatic hypertrophy, mild cognitive impairment, chronic kidney disease, and congestive heart failure. CK level peaked 12,203 U/L, and later dropped gradually to normal levels. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. In the article previously mentioned, Galanopoulou (33) described, on May 06, 2020, epileptical activity on EEG of two patients, one with a subdural hematoma and one with subarachnoid hemorrhage secondary to aneurism, in patients positive for COVID-19. Other details were already explained above. Doctors from New York, USA, describe three cases on May 06, 2020 (59) , with arterial thromboembolic complications despite prophylaxis, of which two consisted of ischemic strokes. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint In its fourth version, from March 25, 2020 (60) The European Academy of Neurology has provided Scientific Panel Statements for Diseases Groups (61), as well. For epilepsy, it is stated that, this far, there is no proof that people with epilepsy are more prone to infection, nor that COVID-19 can trigger seizures. For Neurocritical care, a concern in the rise in subacute neurological complications, such as GBS and encephalitis is manifested. As an increase in stroke incidence is a major concern, the American Heart Association has issued Temporary Emergency Guidance (62) to US Stroke Centers. Attention is drawn to the fact that Stroke patients may have asymptomatic or faint respiratory complaints, so physicians should be aware of this matter and consider testing for COVID-19 in these cases. Due to the shortage of ICU beds worldwide, it is advised that . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Of all neurologic complications, stroke is a major concern, as there is at this point a trend in the rise of neurovascular cases, especially stroke from large arteries and to a great extent in young patients. Although the pathophysiology is still not fully explained, it is known that patients with COVID-19 are prone to a hypercoagulability or dyscrasia states, in the same fashion as happens with other viruses, such as HIV (68), cytomegalovirus, varicella-zoster (69), Hepatitis C, Epstein-Barr (70), SARS-CoV (6) and MERS-CoV (10). Of the 43 mentioned cases of stroke, 38 (88%) were ischemic, and the remaining 5 (22%) were hemorrhagic. This series is proportional to data previously described of vascular events unrelated to infections, that is, the ratio of ischemic to hemorrhagic strokes, in neurovascular services, is usually between 80 to 90% ischemic to 10-20% hemorrhagic strokes, which could raise a suspicion that, in a few cases, infection of COVID-19 could be coincidental. However, this line of though seems to be invalid for most cases, due to the undoubtful increase in cases of young people, or people without comorbidities that raise the risk of stroke, to the occurrence of multi infarctions in both hemispheres, without proven cardioembolic etiology, usually the culprit in bilateral manifestations, and to the confirmation by some author, like Kiok, of a greater than usual incidence of thrombotic complications of any sort (not only neurological). Special attention to immediate care and, to thrombolysis or thrombectomy should be sought in cases of ischemic stroke, especially the ones from large cerebral arteries, prone to graver outcomes and death. On the other hand, the greater risk of bleedings, due to the coronavirus septic, dyscrasic state, is to be considered. Finally, higher risk of renal impairment by the multi-organ failure due to SARS-CoV-2 is worrying, especially in patients receiving iodine contrast for CTs and angiographies, and plays against optimal outcomes from stroke. Specifically, about anosmia, it is probable that trans-synaptic (or transcribrial) invasion, proposed by Baig et al. (71) , i.e., via axonal, retrograde path of the olfactory nerve, explains only partially this symptom, as many patients that display loss of smelling also . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint manifest loss of taste (dysgeusia), because the latter has nothing to do with olfactory bulb invasion by the virus, and also to the fact that, in one case, Galougahi performed an MRI of a patient with COVID-19 and found no alterations in the olfactory bulb -more cases with imaging are needed to warrant the confirmation of no acute injury detected in the olfactory bulb. Dysgeusia could be due to edema and/or inflammation, as happens with other airborne infections, but also to direct damage of gustatory papillae (taste buds), in the same fashion of invasiveness to the olfactory nerve, by binding to ACE-2 receptors, as theorized by Finsterer and Stollberger (72) . Moreover, it is not clear how patients with anosmia could be less prone to severe forms of COVID-19, as the study by Yan et al. found. One theoretical explanation is that, in patients where trans-synaptic invasion occurs, nervous system damage by other pathways, i.e., via bloodstream or cytokine storm, as proposed by Wu et al. (73) , is mitigated. However, this needs further exploration and research. Also, the prevalence of anosmia varied widely in studies, -5.1%, 35%, 47%, 58.6% and 75%, in 5 reportsinferring that it may be possible that milder degrees of smell impairment go unnoticed, as the study leaded by Moein concludes, after confronting self-declaration and diagnosis after application of the UPSIT test, which is more reliable than self-awareness of smell loss. Regarding GBS, it is becoming increasingly clear that neurological deficits from polyneuropathy may arise earlier than expected, to the extreme of starting before respiratory symptoms, as reported by Zhao. This case, specifically, is an odd manifestation, as the vast majority of neurological symptoms in GBS start weeks after the original infection (usually, but not exclusively, respiratory or from the gastrointestinal tract, or systemic like in Dengue and Zika viruses). This may be because nerve damage results from direct damage (para-infectious), and not from crossed immunity against components of the myelin sheath or the axon, the usual mechanism of polyneuropathy in GBS. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint Nonetheless, both axonal and demyelinating forms in GBS were observed. In the case of Zhao et al.'s report, although authors consider it to be a demyelinating form, due to absence of some F waves, there is also reduction of amplitude in the antidromic sensitive conduction study of the left median and ulnar nerves, and in the motor conduction study of the left peroneal nerve, which is commonly found in axonal forms, however study was performed on day 5 of symptoms, a bit early to define more precisely, by nerve conduction techniques, the GBS form, and could be repeated later, for better clarification. Finally, Miller-Fisher syndrome, consisting of ataxia, areflexia and ophthalmoplegia (sometimes not all of those) was observed by Gutiérrez-Ortiz and Dinkin. It is noticeable that, although there is a considerable number of guidelines and protocols proposed by sub-specialty associations, a substantial level on uncertainty is perceptible. For instance, there are doubts about maintenance of steroids and at which dosage, and the same applies to ACE-2 inhibitors, widely used by many neurological patients, such as people with muscular dystrophy, stroke and neuroimmune diseases. In this paper we proposed a chronological review of information available of 41 papers of cases and also declarations issued by neurological sub-specialties about the impact of COVID-19, regarding clinical aspects -the prevalence of neurologic symptoms, manifestations in the CNS, PNS, and neurovascular system and guidelines concerning specific handling of disease groups' populations in Neurology. Most of the data, so far, comes from reports from countries where COVID cases were or are significantly high -80% of reports come from China, Italy, Iran and the USA, although reports from other countries start to emerge. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. The prevalence of neurologic symptoms varies widely, so far from 36.4 to 85%, and it seems that patients with severe disease tend to display more frequent alterations of the nervous system than patients with mild or moderate cases. Patients with a particular complaint -anosmia, seemed less prone to aggravation and need of hospitalization, as one study found that patients that were hospitalized were more frequently with intact olfactory and gustatory senses. Prevalence of this symptom varied widely -5.1t %o 75%, in five different reports. Data published so far points to less severity of neurological complications in 80-90% of times patients manifest a non-life-threatening neurological complaint, and the remaining might require hospitalization and are in risk of sequelae and even death. Among the latter, stroke is a major concern, as there is at this point, although still not clearly explained in terms of pathophysiology, a trend in the rise of neurovascular cases, and up to 5% of patients with COVID could manifest stroke, especially brain ischemia from large arteries, and also cases in young patients with little or no comorbidities. With time, we expect to have a much broader learning of explanations for the causality of neurological symptoms by the new coronavirus, due to more publications and also to better strength and quality of further published papers, with more detailed and precise descriptions, which tend to be peer-reviewed and vetted. Also, recommendations from specialized organizations and associations tend to come with greater level of certainty. Finally, acknowledging the fact that, among all patients with neurological complications, RT-PCR for COVID-19 was positive in the CSF in only one patient arises an intriguing question and needs further elaboration. Authors declare no conflicts of interest regarding the subjects discussed in this paper. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint Appendix 1 - Tables TABLE 1 Strain First Author (COUNTRY) Year of publication . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Rhabdomyolysis (CK up to ~ 12,000) in an 88-yo male with multiple comorbidities . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Two ischemic strokes in patients that were receiving enoxaparin 40 mg subcutaneously. One in a 50-yo man (right parietal lobe), the other in a 69-yo man (left thalamus) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. 2 Dinkin . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.19.20107102 doi: medRxiv preprint A Novel Coronavirus from Patients with Pneumonia in China Coronavirus Mortality Rate (COVID-19) -Worldometer World Health Organization. World Health Organization Covid Dashboard Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Neurological manifestations in severe acute respiratory syndrome Olfactory Neuropathy in Severe Acute Respiratory Syndrome: Report of A Case Neurological Complications during Treatment of Middle East Respiratory Syndrome Neurological Complications of Middle East Respiratory Syndrome Coronavirus: A Report of Two Cases and Review of the Literature Neurological Associations of COVID-19. The Lancet Neurology Human Coronavirus OC43 Associated with Fatal Encephalitis Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Neurologic Features in Severe SARS-CoV-2 Infection Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus [Internet Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019 China: Wuhan Coronavirus hospital built in just 10 days -watch Steroid-responsive severe encephalopathy in SARS-CoV-2 infection | medRxiv Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles COVID-19-Associated Acute Disseminated Encephalomyelitis: A Case Report. medRxiv Neurologic manifestations in an infant with COVID-19 COVID-19 Presenting with Seizures. IDCases EEG findings in acutely ill patients investigated for SARS-CoV2/COVID-19: a small case series preliminary report. Epilepsia Open Two patients with acute meningo-encephalitis concomitant to SARS-CoV-2 infection Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study | SpringerLink Features of anosmia in COVID-19. Médecine Mal Infect Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol Self-reported olfactory loss associates with outpatient clinical course in Covid-19 Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Guillain-Barré Syndrome Associated with SARS-CoV-2 Guillain-Barré syndrome related to COVID-19 infection. Neurol -Neuroimmunol Neuroinflammation Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVIDhospital Miller Fisher Syndrome and polyneuritis cranialis in COVID-19 | Neurology COVID-19 presenting with ophthalmoparesis from cranial nerve palsy Early Release -Rhabdomyolysis as Potential Late Complication Associated with COVID-19 Rhabdomyolysis as a Presentation of Novel Coronavirus Disease Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study Social Science Research Network Three unsuspected CT diagnoses of COVID-19 Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Cerebrovascular complications in patients with SARS-CoV-2 infection: Case series Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 | NEJM Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young COVID-19 presenting as stroke Emergency Room Neurology in times of COVID-19: Malignant Ischemic Stroke and SARS-COV2 Infection Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis Association of British Neurologists. Association of British Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and carers Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel TeleStroke units serving as a model of care in rural areas: 10-year experience of the TeleMedical project for integrative stroke care Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 epidemic in China: a web-based cross-sectional survey Dealing with sleep problems during home confinement due to the COVID-19 outbreak: practical recommendations from a task force of the European CBT-I Academy COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet HIV infection, hypercoagulability and ischaemic stroke in adults at the University Teaching Hospital in Zambia: a case control study Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Lechien (BELGIUM) 417 mild and moderate cases of COVID, anosmia and dysgeusia were present in 85